Scarica l'app Stockscreener
3.54
6.35%
-0.24
Precedente Chiudi:
$3.78
Aprire:
$3.79
Volume 24 ore:
40,547
Relative Volume:
0.98
Capitalizzazione di mercato:
$19.19M
Reddito:
-
Utile/perdita netta:
$-2.17M
Rapporto P/E:
-0.2041
EPS:
-17.3434
Flusso di cassa netto:
$-4.82M
1 W Prestazione:
+7.16%
1M Prestazione:
+59.20%
6M Prestazione:
-23.62%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.50
$3.89
Intervallo di 1 settimana:
$3.36
$4.77
Portata 52W:
$1.8299
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
3.59 | 19.19M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
705.22 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
798.92 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
302.01 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newcelx Ltd Borsa (NCEL) Ultime notizie
How NewcelX (NCEL) differentiates itself from competitors (Investor Concern) 2026-05-05Community Driven Stock Picks - Newser
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Yahoo Finance
Olivier Samuel Buys Handful Of Shares In NewcelX - 富途牛牛
Despite NewcelX's Pullback, Insiders Still Gained ₪136k - Yahoo Finance
NewcelX Loses US$2.3m Market Value But Insiders See Windfall Of ₪136k - simplywall.st
NCEL | NewcelX Ltd. Ordinary Shares Insider Trading - Quiver Quantitative
NewcelX Ltd. announced that it has received $1.349994 million in funding - marketscreener.com
NCEL - Finviz
NewcelX Posts 2025 Results and Bolsters Funding to Accelerate Type 1 Diabetes Program - TipRanks
Newcelx Reports Financial Results for 2025 an - Moomoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - The Manila Times
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans - Quiver Quantitative
NewcelX makes Type 1 diabetes program its 2026 flagship - Stock Titan
Insider Buying: Olivier Samuel Acquires 81,818 Shares of NewcelX Ltd (NCEL) - GuruFocus
NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NewcelX (NCEL) 20-F: Kadimastem merger, heavy losses and funding risk - Stock Titan
NewcelX Ltd. (NCEL) Stock Price Today - MEXC Exchange
NCEL Should I Buy - Intellectia AI
NewcelX (NCEL) Trend Analysis | Q1 2025: Earnings ReportDividend Report - Cổng thông tin điện tử tỉnh Lào Cai
NewcelX updates presentation on diabetes therapy collaboration By Investing.com - Investing.com India
Newcelx updates corporate presentation to highlight type 1 diabetes flagship program - marketscreener.com
NewcelX Highlights Type 1 Diabetes Flagship and Eledon Collaboration in Updated April 2026 Presentation - TipRanks
NewcelX updates presentation on diabetes therapy collaboration - Investing.com
NewcelX Ltd. Enhances Type 1 Diabetes Program with Strategic Collaboration with Eledon Pharmaceuticals - Quiver Quantitative
[6-K] NewcelX Ltd. Current Report (Foreign Issuer) | NCEL SEC FilingForm 6-K - Stock Titan
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - The Manila Times
NewcelX heads to Swiss Biotech with a Type 1 diabetes strategy - Stock Titan
NewcelX (NCEL) Stock Equalweight (Runs Up) 2026-04-18High Interest Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Liora Oren Net Worth (2026) - GuruFocus
Eran Israel Iohan Net Worth (2026) - GuruFocus
Olivier Samuel Net Worth (2026) - GuruFocus
Tamar Galili Net Worth (2026) - GuruFocus
Alexander Zwyer Net Worth (2026) - GuruFocus
Ronen Twito Net Worth (2026) - GuruFocus
Kfir Molakandov Net Worth (2026) - GuruFocus
Michel Revel Net Worth (2026) - GuruFocus
Omri Hagai Net Worth (2026) - GuruFocus
Should I Buy NewcelX (NCEL) Stock Now | Price at $2.58, Up 3.61%High Reward Trade - Newser
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Quantisnow
NewcelX Ltd. (NCEL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NCEL Q1 2025 Earnings: NewcelX Ltd. Ordinary Shares reports -6.34 EPS no estimates or revenue filedROCE - Newser
Is NewcelX (NCEL) Stock Ready to Rally | Price at $2.27, Up 0.67%Breakout Stocks - Newser
NCEL SEC FilingsNewcelX Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NewcelX Ltd.Ordinary Shares (NQ: NCEL - The Chronicle-Journal
NewcelX raises $1.35M in private placement at 30% premium By Investing.com - Investing.com Australia
NewcelX Raises $1.35 Million in Premium-Priced Private Placement to Advance Type 1 Diabetes Program - TipRanks
NewcelX Ltd. announced that it expects to receive $1.349994 million in funding - marketscreener.com
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing - bitget.com
NewcelX raises $1.35M in private placement at 30% premium - Investing.com
Newcelx Ltd Azioni (NCEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Newcelx Ltd Azioni (NCEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Revel Michel | CSO and Director |
Apr 27 '26 |
Buy |
2.75 |
54,545 |
149,999 |
957,530 |
0.14%
2.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):